Biaoxue Rong,1 Tian Fu,2 Wenlong Gao,3 Min Li,4 Congxue Rong,5 Wen Liu,6 Hua Liu7
1Department of Oncology and Gerontology, First Affiliated Hospital, Xi’an Medical University, Xi’an, People’s Republic of China; 2Department of Respiratory Medicine, Jining No.1 People’s Hospital, Jining, People’s Republic of China; 3Institute of Epidemiology and Health Statistics, School of Public Health, Lanzhou University, Lanzhou, People’s Republic of China; 4Nursing Department, Binhe New District Branch, Shenmu Hospital, Yulin City, Shaanxi, People’s Republic of China; 5Comprehensive Medical Department, Zhangye Second People Hospital, Zhangye, People’s Republic of China; 6Department of Respiratory Medicine, Minqin County People’s Hospital, Minqin, People’s Republic of China; 7Department of Respiratory Medicine, Gansu Provincial Hospital, Lanzhou, People’s Republic of China
Correspondence: Biaoxue Rong
Department of Oncology and Gerontology, First Affiliated Hospital, Xi’an Medical University, 48 Fenghao West Road, Xi’an 710077, People’s Republic of China
Tel +86 29-87679300
Email [email protected]
Background: The aim of this study was to reveal the correlations between serum concentration of Clara cell secretory protein (CC16) and clinical parameters of stable chronic obstructive pulmonary disease (COPD).
Patients and Methods: Serum concentration of CC16 was determined by enzyme-linked immunosorbent assay (ELISA). The correlations between serum concentration of CC16 and clinical parameters was performed by linear correlation analysis and multiple linear regression analysis. The sensitivity and specificity of serum CC16 for differential diagnosis of COPD were determined by receiver operator characteristic curve (ROC).
Results: The serum concentration of CC16 was down-regulated in stable COPD patients compared with healthy control group (p < 0.05). The decreased serum CC16 was negatively related to smoking (p < 0.05), GOLD grading (p < 0.005), mMRC score (p < 0.05) and medical history (p < 0.05) of patients, but positively correlated with pulmonary function (p < 0.05). The smoking, FEV1/FVC values, COPD grading and mMRC scores all affected the concentration of CC16 (p < 0.05). The decreased CC16 was an independent risk factor in the process of deterioration of lung function. The sensitivity and specificity of serum CC16 for identifying COPD reached to 65.3% and 75%.
Conclusion: Decreased serum concentration of CC16 correlated with the disease progression of COPD, suggesting that it can be used as an indicator contributing to the diagnosis and assessment of COPD.
Keywords: chronic obstructive pulmonary disease, COPD, Clara cell secretory protein 16, CC16
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.